Cephaloridine

Chemical compound

Engineered Monoclonal Antibodies

Diagram of engineered monoclonal antibodies

Engineered monoclonal antibodies are a class of biological therapies that are designed to target specific antigens on the surface of cells. These antibodies are produced using recombinant DNA technologies and are used in the treatment of various diseases, including cancer, autoimmune disorders, and infectious diseases.

Structure and Function

Monoclonal antibodies are composed of two identical heavy chains and two identical light chains, forming a Y-shaped molecule. The tips of the "Y" contain the antigen-binding sites, which are highly specific to the target antigen. This specificity allows monoclonal antibodies to bind to their target with high affinity, blocking or modulating the function of the antigen.

Types of Engineered Monoclonal Antibodies

There are several types of engineered monoclonal antibodies, each designed for specific therapeutic purposes:

• Chimeric antibodies: These antibodies are composed of murine (mouse) variable regions and human constant regions. They are less immunogenic than fully murine antibodies.

• Humanized antibodies: These antibodies are mostly human, with only the antigen-binding sites derived from murine sources. This reduces the risk of immune reactions.

• Fully human antibodies: These are entirely human in origin, produced using transgenic mice or phage display technologies.

• Bispecific antibodies: These antibodies are engineered to bind two different antigens simultaneously, offering unique therapeutic mechanisms.

Applications in Medicine

Engineered monoclonal antibodies have revolutionized the treatment of many diseases:

• Cancer therapy: Monoclonal antibodies can target specific tumor antigens, leading to direct tumor cell killing or recruitment of immune cells to attack the tumor.

• Autoimmune diseases: By targeting specific components of the immune system, monoclonal antibodies can reduce inflammation and tissue damage in diseases such as rheumatoid arthritis and multiple sclerosis.

• Infectious diseases: Monoclonal antibodies can neutralize pathogens or their toxins, providing passive immunity or enhancing the host's immune response.

Production

The production of engineered monoclonal antibodies involves several steps:

1. Antigen identification: The target antigen is identified and characterized. 2. Hybridoma technology: B cells from immunized animals are fused with myeloma cells to create hybridomas that produce the desired antibody. 3. Recombinant DNA technology: Genes encoding the antibody are cloned and expressed in suitable host cells, such as Chinese hamster ovary cells. 4. Purification and formulation: The antibodies are purified and formulated for clinical use.

Challenges and Future Directions

While engineered monoclonal antibodies have shown great promise, there are challenges such as high production costs, potential for immune reactions, and the development of resistance. Ongoing research aims to improve antibody design, reduce immunogenicity, and enhance therapeutic efficacy.

Related Pages

• Monoclonal antibody therapy
• Biopharmaceutical
• Immunotherapy
• Hybridoma technology

Cephaloridine is a first-generation Cephalosporin antibiotic, introduced in the 1960s. It is a beta-lactam antibiotic similar in structure and mechanism of action to penicillins. Cephaloridine was developed for the treatment of bacterial infections due to its effectiveness against a broad range of Gram-positive bacteria and some Gram-negative bacteria. However, its use has declined over the years due to the development of newer antibiotics with fewer side effects and broader antimicrobial activities.

Chemical Structure and Mechanism of Action

Cephaloridine's chemical structure is characterized by a beta-lactam ring, which is essential for its antibacterial activity. The mechanism of action of cephaloridine involves the inhibition of bacterial cell wall synthesis. It binds to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, leading to the disruption of cell wall synthesis and ultimately causing cell lysis and death.

Pharmacokinetics

The pharmacokinetics of cephaloridine involve its absorption, distribution, metabolism, and excretion. After administration, cephaloridine is not well absorbed from the gastrointestinal tract and is therefore usually administered via intramuscular or intravenous injection. It is distributed throughout the body, including in the kidneys, liver, and lungs. Cephaloridine is excreted primarily by the kidneys through glomerular filtration.

Clinical Uses

Cephaloridine was primarily used to treat infections caused by susceptible bacteria, including respiratory tract infections, skin and soft tissue infections, urinary tract infections, and bone and joint infections. Its use has been largely superseded by newer cephalosporins and other antibiotics that have a broader spectrum of activity and are less nephrotoxic.

Side Effects and Toxicity

The most significant adverse effect associated with cephaloridine is nephrotoxicity, which can lead to kidney damage, particularly at high doses or in patients with pre-existing kidney impairment. Other side effects may include allergic reactions, ranging from rash to anaphylaxis, as well as gastrointestinal disturbances such as nausea, vomiting, and diarrhea.

Current Status

Due to its nephrotoxic effects and the availability of safer, more effective antibiotics, the use of cephaloridine has decreased significantly and it is no longer widely used in clinical practice. Research into cephalosporins has continued, leading to the development of several generations of these antibiotics, each with improved spectra of activity and safety profiles.

This article is a stub. You can help WikiMD by registering to expand it. Editing is available only to registered and verified users. WikiMD is a comprehensive, free health & wellness encyclopedia.

• 

  Cephaloridine